Human Alpha1-Proteinase Inhibitor

7 trials 3 recruiting BHaematology Orphan designation

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

3 Completed trials

6 Sponsors

11 Countries

Phase III

Phase II/III

Phase II

Phase IV

Phase III: 2 Phase II/III: 1 Phase II: 3 Phase IV: 1

Indications tested

Alpha-1 antitrypsin deficiency 1 Graft versus host disease 1 Emphysema 1

Sponsors using this IMP

CSL Behring LLC 2 Fondazione IRCCS Policlinico San Matteo 1 Grifols Therapeutics LLC 1 Kamada Ltd. 1 Medizinische Universitaet Innsbruck 1 Sanofi AATD Inc. 1

All trials

7 total

Phase 4, double-blind study evaluating the response on computed tomography (CT) lung density decline rates of Respreeza / Zemaira weekly for… Pending

2025-522964-33-00 Phase IV 1 country CSL Behring LLC
A two-center, randomized, double-blind, placebo-controlled study of intravenous plasma-purified alpha-1 antitrypsin for hospitalized patient… Recruiting

2024-517613-33-00 Phase II 1 country Fondazione IRCCS Policlinico San Matteo
Safety and clinical parameter assessment of self-infusion therapy with Prolastin® in patients with severe AATD Recruiting

2024-515894-80-00 Phase III 1 country Grifols S.A.
Effect of Alpha-1 Antitrypsin Supplementation in Alcohol-Associated Hepatitis-A prospective Pilot Study Recruiting

2024-515794-99-00 Phase II 1 country Medizinische Universitaet Innsbruck
Phase 2 study comparing SAR447537 to plasma-derived A1PI therapy for AATD emphysema Ended

2023-508084-76-00 Phase II 5 countries Sanofi AATD Inc.
A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of "Kamada-AAT for I… Ended

2024-516054-21-00 Phase III 5 countries Kamada Ltd.
The safety and efficacy of Alpha-1 Antitrypsin (AAT) for the prevention of graft‑versus-host disease (GVHD) in patients receiving hematopoie… Ended

2024-511164-92-00 Phase II/III 3 countries CSL Behring LLC

Showing 1–7 of 7 trials

← All drugs A–Z